Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIB-626 in Adults With Down Syndrome
NCT07278492Phase 1Not yet recruiting
- Sponsor
- Brigham and Women's Hospital
- Start
- Aug 2026
- Primary completion
- Feb 2028
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of liposomal β-nicotinamide mononucleotide in Alzheimer's disease (AD) (2 arms), sponsored by Brigham and Women's Hospital. Primary endpoints: Treatment emergent adverse events and Treatment emergent serious adverse events. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
liposomal β-nicotinamide mononucleotide
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07278492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07278492.